IL5 signalling in asthma

IL5 signalling in asthma

Project details

Mepolizumab is a drug used to treat asthma, a disease driven by eosinophils. The drug works by blocking IL-5, the cytokine regulating eosinophils. Mepolizumab rapidly decreases the number of eosinophils in the blood but has much less effect on lung eosinophil numbers. 

We will assess the ability of anti-IL5 drugs to permeate the lung. We will also perform RNAseq analyses to determine which genes downstream of cytokine signalling are active in lung eosinophils compared to blood or bone marrow eosinophils, and which cell survival proteins are expressed in an effort to understand why peripheral but not lung eosinophils are depleted by anti-IL5 treatment.

The successful applicant will learn molecular, cellular and quantitative biological methods. They will also have the chance to perform state-of-the art imaging.

About our research group

The Hilton laboratory studies the development and function of blood cells, with a current focus on granulocytes. We aim to identify genes and molecular pathways that are important in regulating normal blood cell production and understand the changes that lead to blood cell disorders such as autoimmunity, inflammatory diseases, and leukemia. We work with clinicians and industry partners to find better ways of treating these illnesses.

We take a multidisciplinary approach combining cell biology, physiology, biochemistry and molecular biology, genomics, bioinformatics and computational science to understand the blood cell system and its individual lineages. We also develop software that assists biologist in visualising and interacting with large data sets. We have a team of talented motivated post-docs ready to teach you the latest techniques.




Professor Doug Hilton

Professor Doug Hilton at the Institute
Institute Director, Division Head
Dr Kirsten Fairfax profile photo
Molecular Medicine division
Dr Carolyn deGraaf profile photo
Molecular Medicine division

Project Type: